贵州茅台，控股股东增持

Group 1: Company News - China Shipbuilding announced that the A-shares of China Heavy Industry will be delisted on September 5, 2023, due to voluntary termination of listing, and will not enter the delisting transition period [4] - Guizhou Moutai's controlling shareholder increased its stake by 67,821 shares on September 1, 2023, representing 0.0054% of the total share capital, with an investment amount of 100 million yuan [4] - BYD reported August sales of 373,600 new energy vehicles, slightly up from 373,100 units in the same month last year [3] - SAIC Motor's August vehicle sales reached 363,400 units, a year-on-year increase of 41.04% [3] - Great Wall Motors sold 115,600 vehicles in August, marking a year-on-year growth of 22.33% [3] - China FAW sold 277,800 vehicles in August, up 3.7% year-on-year [4] - Beijing Electric Vehicle Co., a subsidiary of BAIC Blue Valley, reported sales of 13,500 vehicles in August, a year-on-year increase of 3.47% [4] - Industrial Fulian announced a share buyback of 7.6974 million shares, accounting for 0.04% of the total share capital, with a total expenditure of 147 million yuan [4] - Su Dawei plans to acquire up to 51% of Changzhou Weipu Semiconductor Equipment Co., with an estimated total valuation of the target company not exceeding 1 billion yuan [5] - Tianqi Co. signed a strategic cooperation framework agreement with EVE Energy to build a closed-loop system for lithium battery lifecycle management [5] - Yonghui Supermarket adjusted its fundraising plan for 2025, reducing the total amount from 3.992 billion yuan to 3.114 billion yuan [5] Group 2: Industry News - The Shanghai Futures Exchange will expand the trading scope for qualified foreign institutional investors starting September 10, 2023, adding several commodity futures and options contracts [1] - The China Banking Association reported that by the end of 2024, there will be 67 financial leasing companies with total assets and leasing assets reaching 4.58 trillion yuan and 4.38 trillion yuan, respectively, reflecting year-on-year growth of 9.65% and 10.24% [1][2] - The biopharmaceutical market in China has become the second largest globally, with approximately 30% of the world's innovative drugs under research [2]